• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    7/3/24 11:41:38 AM ET
    $ACCD
    Business Services
    Consumer Discretionary
    Get the next $ACCD alert in real time by email
    SC 13G/A 1 ACCOLADE_INC.htm FILING ACCOLADE, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 02)*
     
    ACCOLADE, INC. 

    (Name of Issuer)
     
    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     
    00437E102

    (CUSIP Number)
     
    June 28, 2024

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  00437E102            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      2,655,831
         
    6   SHARED VOTING POWER
       
      2,221
         
    7   SOLE DISPOSITIVE POWER
       
      2,955,446
         
    8   SHARED DISPOSITIVE POWER
       
      2,221
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      2,957,785
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      3.6 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    ACCOLADE, INC.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    1201 Third Avenue, Suite 1700,
    Seattle, WA 98101


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.0001 par value per share


     
    (e)
    CUSIP Number
     
     
    00437E102


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 2,957,785


     
    (b)
    Percent of class: 3.6 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 2,655,831


     
    (ii)
    Shared power to vote or to direct the vote: 2,221


     
    (iii)
    Sole power to dispose or to direct the disposition of: 2,955,446


     
    (iv)
    Shared power to dispose or to direct the disposition of: 2,221


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Trust Company of Delaware
    JPMorgan Chase Bank, National Association
    J.P. MORGAN SE
    J.P. Morgan (Suisse) SA
    J.P. Morgan Investment Management Inc.
    J.P. Morgan Private Wealth Advisors LLC
    55I, LLC
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: July 03, 2024
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD

    DatePrice TargetRatingAnalyst
    6/28/2024$13.00 → $8.00Buy
    Needham
    2/26/2024$16.00Outperform
    Leerink Partners
    1/17/2024$16.00 → $14.00Neutral
    DA Davidson
    1/3/2024$13.00Equal Weight
    Barclays
    5/24/2023$16.50Neutral → Buy
    BofA Securities
    4/12/2023$18.00Overweight
    Stephens
    3/23/2023$16.00Neutral → Buy
    Guggenheim
    2/9/2023$14.00Buy → Hold
    Jefferies
    More analyst ratings

    $ACCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Completes Merger With Accolade

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Stockholders Approve Merger Between Accolade and Transcarent

    SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol

    3/27/25 4:05:00 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

    Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

    3/6/25 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Accolade with a new price target

    Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously

    6/28/24 7:50:50 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Accolade with a new price target

    Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00

    2/26/24 7:00:19 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    DA Davidson resumed coverage on Accolade with a new price target

    DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously

    1/17/24 7:07:47 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:52:21 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Lepore Dawn G

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:37:34 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Director Kent Cindy returned $84,093 worth of shares to the company (11,962 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:36:43 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    SEC Filings

    View All

    SEC Form 15-12G filed by Accolade Inc.

    15-12G - Accolade, Inc. (0001481646) (Filer)

    4/18/25 9:10:20 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Accolade Inc.

    25-NSE - Accolade, Inc. (0001481646) (Subject)

    4/8/25 3:43:21 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Leadership Updates

    Live Leadership Updates

    View All

    Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

    SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar

    2/24/25 5:20:27 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

    Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo

    9/18/23 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade appoints new chief information security officer

    With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en

    7/25/22 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Financials

    Live finance-specific insights

    View All

    Transcarent To Acquire Accolade

    Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil

    1/8/25 8:30:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade to Announce Fiscal Third Quarter 2025 Financial Results

    SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li

    12/16/24 8:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Announces Results for Fiscal Second Quarter 2025

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s

    10/8/24 7:00:29 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/12/24 12:26:15 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Accolade Inc.

    SC 13G - Accolade, Inc. (0001481646) (Subject)

    11/4/24 11:51:44 AM ET
    $ACCD
    Business Services
    Consumer Discretionary